Monoamine oxidase inhibitors--current status.
D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology; D001923:Brain Chemistry / Q000187:drug effects; D002395:Catecholamines / Q000378:metabolism; D055598:Chemical Phenomena; D002621:Chemistry; D003010:Clorgyline / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy; D004347:Drug Interactions; D006801:Humans; D006834:Hydrazines / Q000494:pharmacology; D006973:Hypertension / Q000139:chemically induced; D007700:Kinetics; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D010698:Phobic Disorders / Q000188:drug therapy; D011941:Receptors, Adrenergic / Q000187:drug effects; D011985:Receptors, Serotonin / Q000187:drug effects; D012642:Selegiline / Q000627:therapeutic use; D014439:Tyramine / Q000009:adverse effects
D000929:Antidepressive Agents, Tricyclic; D002395:Catecholamines; D006834:Hydrazines; D008996:Monoamine Oxidase Inhibitors; D011941:Receptors, Adrenergic; D011985:Receptors, Serotonin; D012642:Selegiline; D003010:Clorgyline; D014439:Tyramine